Valuation: Sutro Biopharma, Inc.

Market Cap 401M 348M 324M 298M 562M 38.23B 571M 3.82B 1.5B 19.03B 1.5B 1.47B 63.82B P/E 2026 *
-2.83x
P/E 2027 * -3.29x
Enterprise Value 401M 348M 324M 298M 562M 38.23B 571M 3.82B 1.5B 19.03B 1.5B 1.47B 63.82B EV / Sales 2026 *
8.99x
EV / Sales 2027 * 12.7x
Free-Float
97.74%
Yield 2026 *
-
Yield 2027 * -
1 day-2.62%
1 week+5.64%
1 month-27.20%
3 months-34.00%
6 months+61.67%
Current year+108.90%
1 week 22.83
Extreme 22.83
25.07
1 month 21.72
Extreme 21.72
33.35
Current year 10.15
Extreme 10.15
43.85
1 year 7.15
Extreme 7.15
43.85
3 years 5.23
Extreme 5.231
61.3
5 years 5.23
Extreme 5.231
237
10 years 5.23
Extreme 5.231
283
Manager TitleAgeSince
Chief Executive Officer 55 2025-03-12
Director of Finance/CFO 53 2025-06-01
Chief Tech/Sci/R&D Officer - 2025-12-31
Director TitleAgeSince
Director/Board Member 70 2009-07-31
Director/Board Member 67 2017-01-31
Director/Board Member 51 2018-07-24
Date Insider Type Main position Quantity % Market Cap.
3/1/26 Fiscal year

Chief Technology Officer

54,569 0.3330%
3/1/26 Fiscal year

Chief Administrative Officer

46,717 0.2851%
3/1/26 Fiscal year

Chief Executive Officer

240,926 1.4702%
Change 5-day change 1-year change 3-year change Capi.($)
-2.62%+5.64%+200.14%-45.93% 401M
+2.35%+2.74%+33.41%+79.20% 56.54B
-0.21%-7.38%+25.34%+63.02% 53.6B
-2.44%+1.40%-15.74%-16.80% 22.91B
-2.85%-7.78%-8.09%+346.36% 21.37B
+2.49%-0.92%+20.31%-12.15% 20.27B
+0.79%-1.06%+29.29%-33.32% 17.56B
+0.58%-5.88%+16.30%+540.37% 14.75B
-5.25%-4.23%+46.41%+169.05% 13.33B
+3.41%-6.61%+163.08%+280.43% 13.53B
Average -0.37%-2.85%+51.04%+137.02% 23.43B
Weighted average by Cap. +0.23%-2.95%+28.96%+119.70%

Financials

2026 *2027 *
Net sales 44.56M 38.74M 36.06M 33.1M 62.52M 4.25B 63.48M 425M 167M 2.12B 167M 164M 7.1B 31.56M 27.43M 25.53M 23.44M 44.27M 3.01B 44.96M 301M 118M 1.5B 119M 116M 5.03B
Net income -137M -119M -111M -102M -193M -13.11B -196M -1.31B -514M -6.53B -516M -504M -21.88B -150M -131M -122M -112M -211M -14.36B -214M -1.43B -563M -7.15B -565M -552M -23.97B
Net Debt - -
Logo Sutro Biopharma, Inc.
Sutro Biopharma, Inc. is an oncology company engaged in developing site-specific and novel-format antibody drug conjugates (ADCs), enabled by its proprietary integrated cell-free protein synthesis platform, XpressCF, and its site-specific conjugation platform, XpressCF+. It designs and develops therapeutics using the relevant and potent modalities, including ADCs, bispecific ADCs, immunostimulatory ADCs, and dual conjugate ADCs. Enabled through its XpressCF and XpressCF+ platforms, it has entered multi-target, product-focused collaborations with pharmaceutical and biotechnology companies in the field of oncology, with its ongoing relationships that include licensing to Ipsen, on an exclusive basis, the right to research, develop, manufacture and commercialize STRO-003. STRO-003 is developed for the treatment of solid tumors. Its XpressCF and XpressCF platforms supports Vaxcyte, focused on discovery and development of vaccines for the treatment and prophylaxis of infectious disease.
Employees
133
Date Price Change Volume
26-07-31 US$24.17 -2.62% 163,209
26-07-30 US$24.82 +6.43% 148,474
26-07-29 US$23.32 -1.73% 187,271
26-07-28 US$23.73 -1.17% 245,881
26-07-27 US$24.01 +4.94% 220,415
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
24.17USD
Average target price
47.75USD
Spread / Average Target
+97.56%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. STRO Stock